Pharsight

Klisyri patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8236799 ALMIRALL Biaryl compositions and methods for modulating a kinase cascade
Dec, 2025

(1 year, 10 months from now)

US8980890 ALMIRALL Compositions and methods of treating cell proliferation disorders
Dec, 2025

(1 year, 10 months from now)

US7300931 ALMIRALL Compositions for treating cell proliferation disorders
Feb, 2026

(1 year, 11 months from now)

US7851470 ALMIRALL Composition and methods for modulating a kinase cascade
Feb, 2029

(4 years from now)

US10669236 ALMIRALL Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
Sep, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10323001 ALMIRALL Compositions for modulating a kinase cascade and methods of use thereof
Dec, 2027

(3 years from now)

US10617693 ALMIRALL Methods of treating and/or preventing actinic keratosis
Mar, 2038

(14 years from now)

US11497750 ALMIRALL Methods of treating and/or preventing actinic keratosis
Mar, 2038

(14 years from now)

Klisyri is owned by Almirall.

Klisyri contains Tirbanibulin.

Klisyri has a total of 8 drug patents out of which 0 drug patents have expired.

Klisyri was authorised for market use on 14 December, 2020.

Klisyri is available in ointment;topical dosage forms.

Klisyri can be used as topical treatment of actinic keratosis of the face or scalp.

Drug patent challenges can be filed against Klisyri from 2024-12-14.

The generics of Klisyri are possible to be released after 07 September, 2038.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 14, 2025

Drugs and Companies using TIRBANIBULIN ingredient

NCE-1 date: 2024-12-14

Market Authorisation Date: 14 December, 2020

Treatment: Topical treatment of actinic keratosis of the face or scalp

Dosage: OINTMENT;TOPICAL

More Information on Dosage

KLISYRI family patents

Family Patents